• Boston Scientific named Joseph M. Fitzgerald executive vice president and chief operating officer, effective Jan. 1, 2027.
• Fitzgerald will oversee global operations, business units, and regions; he previously served as executive vice president and group president, Cardiovascular.
• Reporting structure will shift to three segments from Jan. 1: Interventional Therapies, Rhythm Solutions, MedSurg.
• Lance Bates will lead Interventional Therapies; Nick Spadea-Anello will lead Rhythm Solutions; Stephen Morse will lead MedSurg and Asia Pacific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070600PR_NEWS_USPR_____NE65521) on October 07, 2026, and is solely responsible for the information contained therein.